Morgan Stanley’s ESSA Pharma EPIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | – | Sell |
-1,904,061
| Closed | -$364K | – | 8280 |
|
|
2025
Q3 | $364K | Sell |
1,904,061
-2,305,609
| -55% | -$2.76M | ﹤0.01% | 5637 |
|
|
2025
Q2 | $7.16M | Sell |
4,209,670
-90,098
| -2% | -$152K | ﹤0.01% | 3761 |
|
|
2025
Q1 | $6.79M | Buy |
4,299,768
+103,899
| +2% | +$176K | ﹤0.01% | 3665 |
|
|
2024
Q4 | $7.51M | Buy |
4,195,869
+14,527
| +0.3% | +$46.3K | ﹤0.01% | 3638 |
|
|
2024
Q3 | $25.3M | Buy |
4,181,342
+3,494
| +0.1% | +$19.2K | ﹤0.01% | 2551 |
|
|
2024
Q2 | $22M | Sell |
4,177,848
-700
| -0% | -$4.45K | ﹤0.01% | 2558 |
|
|
2024
Q1 | $35.5M | Sell |
4,178,548
-8,030
| -0.2% | -$70.1K | ﹤0.01% | 2091 |
|
|
2023
Q4 | $27.6M | Buy |
4,186,578
+3,895
| +0.1% | +$19.2K | ﹤0.01% | 2330 |
|
|
2023
Q3 | $12.9M | Buy |
4,182,683
+312,603
| +8% | +$901K | ﹤0.01% | 2882 |
|
|
2023
Q2 | $10.4M | Buy |
3,870,080
+764,865
| +25% | +$2.24M | ﹤0.01% | 3110 |
|
|
2023
Q1 | $9.22M | Buy |
3,105,215
+1,098,738
| +55% | +$3.23M | ﹤0.01% | 3222 |
|
|
2022
Q4 | $5.06M | Sell |
2,006,477
-99,542
| -5% | -$286K | ﹤0.01% | 3757 |
|
|
2022
Q3 | $3.83M | Sell |
2,106,019
-1,563,661
| -43% | -$4.12M | ﹤0.01% | 3911 |
|
|
2022
Q2 | $11.6M | Buy |
3,669,680
+2,119,150
| +137% | +$11.8M | ﹤0.01% | 2916 |
|
|
2022
Q1 | $9.58M | Buy |
1,550,530
+1,545,497
| +30,707% | +$13.6M | ﹤0.01% | 2952 |
|
|
2021
Q4 | $71K | Sell |
5,033
-108,948
| -96% | -$1.21M | ﹤0.01% | 6629 |
|
|
2021
Q3 | $912K | Sell |
113,981
-382,828
| -77% | -$6.09M | ﹤0.01% | 5106 |
|
|
2021
Q2 | $14.2M | Sell |
496,809
-76,158
| -13% | -$2.21M | ﹤0.01% | 2570 |
|
|
2021
Q1 | $16.6M | Buy |
572,967
+106,253
| +23% | +$2.47M | ﹤0.01% | 2109 |
|
|
2020
Q4 | $5.57M | Buy |
466,714
+119,895
| +35% | +$844K | ﹤0.01% | 3147 |
|
|
2020
Q3 | $2.39M | Buy |
346,819
+220,954
| +176% | +$1.5M | ﹤0.01% | 3492 |
|
|
2020
Q2 | $780K | Buy |
+125,865
| New | +$597K | ﹤0.01% | 4348 |
|
|
2020
Q1 | – | Sell |
-7,589
| Closed | -$42K | – | 6603 |
|
|
2019
Q4 | $42K | Buy |
+7,589
| New | +$35.3K | ﹤0.01% | 5904 |
|
|
2018
Q1 | – | Sell |
-75
| Closed | – | – | 6636 |
|
|
2017
Q4 | $0 | Sell |
75
-500
| -87% | -$2.6K | ﹤0.01% | 6588 |
|
|
2017
Q3 | $3K | Buy |
+575
| New | +$4.01K | ﹤0.01% | 6356 |
|
|
2016
Q2 | – | Sell |
-183
| Closed | -$12K | – | 6546 |
|
|
2016
Q1 | $12K | Hold |
183
| – | – | ﹤0.01% | 6078 |
|
|
2015
Q4 | $15K | Sell |
183
-442
| -71% | -$46.1K | ﹤0.01% | 6120 |
|
|
2015
Q3 | $72K | Buy |
+625
| New | +$87.2K | ﹤0.01% | 5574 |
|
Morgan Stanley's EPIX Position: Q4 2025 in Review
Morgan Stanley sold out of ESSA Pharma (EPIX) in Q4 2025, closing a stake of 1,904,061 shares — an estimated $364K sold.
Morgan Stanley first reported a position in EPIX in Q3 2015 and held it in 28 quarters. The position peaked at $35.5M in Q1 2024. 0 funds tracked by Wall St. Rank hold EPIX as of Q4 2025.
- Morgan Stanley reported no remaining ESSA Pharma position as of Q4 2025 after selling out during the quarter.
- Morgan Stanley sold 1,904,061 ESSA Pharma shares in Q4 2025, an estimated $364K.
- Morgan Stanley first reported a position in ESSA Pharma in Q3 2015 and held it in 28 quarters.
- Morgan Stanley's ESSA Pharma position peaked at $35.5M in Q1 2024.
- 0 funds tracked by Wall St. Rank held ESSA Pharma as of Q4 2025.
Based on Morgan Stanley's 13F filing for Q4 2025, filed 13 Feb 2026.